in a more rapid relapse and shorter OS and DFS. The kinetic characteristics of adult ALL seem to be rather similar to NHL, since NHL with high AgNOR quantity have a poorer prognosis than NHL with low AgNOR quantity.
This work was supported by grants from the Italian Ministero dell'Università e Ricerca Scientifica e Tecnologica (MURST).
A Pich We describe the detection of a single base pair insertion in the HLA-A n 2402 allele in the blast cells of a patient with B-cell acute lymphoblastic leukemia (B-ALL). This mutation resulted in the loss of expression of HLA-A n 2402 on the blast cells. The mutation was not present in the nonleukemia cells on which HLA-A n 2402 was normally expressed. The mutation was detected following HLA typing by DNA sequencing during routine workup for bone marrow transplantation.
There is considerable evidence to suggest that proliferation of tumor cells is controlled in some part by the immune system. This includes tumor cell killing by cytotoxic T lymphocytes following the presentation of tumor-specific peptide by tumor cell HLA. 1 Thus, the loss of expression of HLA molecules on tumor cells may result in a selective advantage for a tumor cell clone and have adverse effects on the course of the disease and efficacy of T-cell-based immunotherapy. The loss or downregulation of HLA on the surface of tumor cells has been reported in many solid organ tumors. However, the loss of HLA in leukemia and lymphoma has been less frequently reported.
The most frequently observed defect resulting in the loss of HLA is the deletion of sections of varying size of the major histocompatibility complex (MHC) from one chromosome.
The loss of a single HLA allele may be sufficient to enable the tumor cell to avoid immune surveillance if this allele presents tumor-specific peptide. However, such loss may go undetected by most molecular HLA typing techniques if the loss is the result of a single base mutation.
In addition, phenotypic detection of allele loss may go undetected unless allele-specific monoclonal antibodies are used, as single allele loss may not result in a quantitative loss of HLA. 2 It is therefore possible that HLA allele loss in leukemia (and other tumors) may occur more frequently than has been previously reported and be a common mechanism of avoiding immune surveillance.
The patient in this study was diagnosed with B-ALL in July 2000. HLA typing was performed as part of a family study to identify a potential bone marrow donor and HLA-A3, A24; B7, B27 were demonstrated by complement-dependent cytotoxicity, and HLA-DRB1 n 1501 and DRB1 n 0803 were demonstrated by DNA sequencing-based typing (SBT). An HLA matched sibling was not found.
Prior to undertaking a search for an unrelated bone marrow donor in July 2002, high-resolution typing for HLA-A, -B, -C, -DRB3-5 and -DQB1 was performed by SBT on stored DNA obtained from the sample collected in July 2000. The HLA-A sequence electropherogram contained a feature consistent with an insertion or deletion (indel) polymorphism in exon 3 ( Figure 1a ). Indel polymorphisms result in complex electropheragram profiles, which are extremely difficult to interpret and provide no clues as to which of the two alleles contain the mutation and whether the mutation is an insertion or a deletion.
In order to determine which of the two HLA-A alleles contained the indel polymorphism, we performed sequencing with primers specific for the HLA-A n 24 allele group and HLA-A n 03 allele group. This resulted in the confirmation of HLA-A n 0301 and the identification of two HLA-A n 24 alleles with one containing a nucleotide insertion relative to the other. Subsequent cloning and sequencing confirmed the presence of three alleles. HLA-A n 0301, HLA-A n 2402 and an allele identical to HLA-A n 2402 (HLA-A n 2402mut) except for a single nucleotide (Guanine, or ''G'') in codon 122 located in exon 3.
To confirm that HLA-A n 2402mut was specific to the B-ALL blast cells, the blast cells and nonleukemic mononuclear cells were sorted from the sample of 31 July 2002 and HLA-A from DNA of both cell populations was sequenced. The results confirmed that DNA from the mononuclear cells contained HLA-A n 0301 and HLA-A n 2402, and the DNA from the leukemic blast cells contained HLA-A n 0301 and the mutant HLA-A n 2402mut allele (Figure 1d) . Translation of the HLA-A n 2402mut sequence did not identify a premature stop codon. However, it is likely that the predicted amino-acid sequence past the point of the inserted nucleotide would completely change the structure of the HLA-A molecule and result in this molecule not being expressed. To confirm that the HLA-A n 2402mut was not expressed on B-ALL blast cells, we performed HLA typing by complement-mediated cytotoxicity on the two populations of cells. The HLA-A24-specific antisera resulted in 100% cytotoxicity of the nonleukemic cells and no cytotoxicity of the CD8-depleted mononuclear cells. These results indicate that HLA-A n 2402mut is not expressed on the B-ALL blast cells.
HLA allele loss as a result of gross chromosomal abnormalities such as the loss of large sections of chromosome 6 that include the MHC 3 are readily detected at the molecular level with the use of polymorphic microsatellite markers. Such mutations, and mutations in accessory genes required for HLA expression, can also be detected at the phenotypic level due to the lack of expression of HLA. The mutation described here is a single base insertion. The phenotypic effects of loss of expression of a single allele are difficult to identify without the use of an extensive panel of allele-specific monoclonal antibodies. The use of monoclonal antibodies to monomorphic determinants is unlikely to be sufficiently quantitative to detect the loss of a single class I allele. 2 The loss or downregulation of HLA molecules in tumor cells which present immunogenic tumor-specific peptides to cytotoxic T cells is a mechanism by which tumor cells evade the immune system. This is supported by recent studies that have shown that HLA on leukemic cells present tumor-specific immunogenic peptide. 1 Furthermore, the HLA molecule encoded by HLA-A We hypothesize that HLA-A n 2402 of the B-ALL cells of the patient described here presented tumor antigen. A somatic insertion mutation occurred in exon 3 of HLA-A n 2402 resulting in the loss of expression and therefore the loss of presentation of the immunogenic tumor peptide to the immune system. This resulted in survival advantage and subsequent proliferation of the B-ALL blast clone containing HLA-A n 2402mut. Single base mutations such as the one described here are much more difficult to detect at the molecular level than haplotype loss and are only likely to be detected by DNA sequencing. The advantages of DNA sequencing are that all nucleotides within the amplified product can be analyzed and thus mutations can also be detected. Other molecular HLA typing procedures, such as amplification with sequence-specific primers (PCR-SSP) or the use of sequence-specific oligonucleotides probes (PCR-SSO), are directed to known polymorphic regions, and the assumed conserved regions and intron sequences are not analyzed. Codon 122 is not polymorphic in HLA-A and as a result it is unlikely that PCR-SSP or PCR-SSO would have detected this mutation. It is possible that HLA allele loss may be frequently missed and therefore occurs more frequently than has been previously reported. The loss of HLA allele expression has important implications for disease progression and treatment with T-cell-based therapies. In addition, these mutations will allow the development of patient-specific molecular-based assays to monitor minimal residual disease. The availability of allele-specific monoclonal antibodies and the increasing routine use of SBT will allow the extent of HLA allele loss to be determined. Hairy cell leukemia (HCL) is a chronic mature B-cell leukemia characterized by splenomegaly, pancytopenia, monocytopenia and pronounced T-cell dysfunction. This T-cell dysfunction can result in autoimmune phenomena as well as severe morbidity caused by both bacterial and viral infectious complications. These T-cell abnormalities have been the subject of study by our group for many years. A remarkable finding was that most T cells of HCL patients lack the costimulatory signal CD28. 1 Furthermore, in many HCL patients, oligoclonal T-cell populations were found with a very restricted and skewed TCRBV repertoire, 2 a phenomenon found in more B-cell malignancies, but not as pronounced as in HCL. This points to a decreased CDR3 diversity and clonogenic expansions of some T cells. Several speculations can be made about the presence and function of the oligoclonal T-cell expansions in HCL patients. Weak expression of adhesion molecules on HCL cells might result in an inadequate immune response and clonal proliferation of T cells recognizing an HCL antigen. Clonal expansions might also originate from an immune response against a persistent systemic or viral infection, which could explain the sensitivity of HCL to interferon (IFN)-alpha. Finally, given the imbalanced immune system, autoreactive T-cell expansions might develop, directed against not only the tumor cells (Spaenij-Dekking, in press), 3 but also against autologous cells of the immune system, for example, B cells, T cells, promonocytes or mature monocytes. Such autoreactivity could explain the pancytopenia with decreased amounts of normal T and B cells, the virtual absence of dendritic cells and monocytes. 4 For characterization of clonal T-cell expansions, we isolated CD3 þ cells of five different HCL patients and determined the sequences of the CDR3 region of a clonal expansion comprising 50% or more of a certain TCRBV family (n ¼ 8). The phenotype of the clonal T-cell expansions before therapy and after restoration of the TCR repertoire was determined by separating CD3 þ T-cell populations before and after INF-a therapy of the different HCL patients into CD8, CD45
RA , CD27, CD28 and CD57 positive and negative populations by FACs sorting, and by studying the presence of cells of the clonally expanded TCRBV T cells by PCR. We found that the in vivo clonal TCRBV cells were only present in the CD8 þ , CD45RA þ , CD27 À , CD28 À and CD57 þ populations, whereas members of the different TCRBV families were present in all sorted populations. A representative example of the experiments is shown in Figure 1 . Therefore, the in vivo clonal T-cell populations in HCL patients, sometimes representing more than 50% of a specific TCRBV family, show a phenotype which has been described for CD8
þ cytotoxic
